"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to DNTH. [ FAQ on what and how to ask] For non-DNTH questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Marino Garcia M.B.A.
Headquarter: 7 Times Square, 43rd Floor, New York, NY, United States, 10036
Industry: Biotechnology, Investment Track: immunity biotech, Employees: 92
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
My Watchlist
